Gold nanorods/siRNA complex administration for knockdown of PARP-1: a potential treatment for perinatal asphyxia

par Vio V, Riveros AL, Tapia-Bustos A, Lespay-Rebolledo C, Perez-Lobos R, Muñoz L, Pismante P, Morales P, Araya E, Hassan N, Herrera-Marschitz M, Kogan MJ
Publié 2018

Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson’s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment

par Rongfang Que, Jialing Zheng, Zihan Chang, Wenjie Zhang, Hualing Li, Zhenchao Xie, Zifeng Huang, Hai-Tao Wang, Jiangping Xu, Dana Jin, Wanlin Yang, Eng-King Tan, Eng-King Tan, Qing Wang, Qing Wang
Publié 2021

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance

par Desh Deepak Singh, Amna Parveen, Dharmendra Kumar Yadav
Publié 2021

The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis

par Francesco Morra, Francesco Merolla, Federica Zito Marino, Rosaria Catalano, Renato Franco, Paolo Chieffi, Angela Celetti
Publié 2021

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

par Inna P. Ganshina, Olga O. Gordeeva, Mariam Sh. Manukian
Publié 2021

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

par Giacomo Barchiesi, Michela Roberto, Monica Verrico, Patrizia Vici, Silverio Tomao, Federica Tomao, Federica Tomao
Publié 2021

The parp-1 and bax genes as potential targets for treatment of the heart functioning impairments induced by type 1 diabetes mellitus

par Kuchmerovska Tamara, Guzyk Mykhailo, Tykhonenko Tetiana, Yanitska Lesya, Pryvrotska Irina, Diakun Kateryna
Publié 2021

Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities

par Haider Mahdi, Amy Joehlin‐Price, Esther Elishaev, Afshin Dowlati, Ata Abbas
Publié 2021

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers

par Anna J. Dellomo, Rachel Abbotts, Christian L. Eberly, Mariusz Karbowski, Maria R. Baer, Tami J. Kingsbury, Feyruz V. Rassool
Publié 2022

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

par T. Hedley Carr, Carrie Adelman, Alan Barnicle, Iwanka Kozarewa, Sally Luke, Zhongwu Lai, Sally Hollis, Brian Dougherty, Elizabeth A. Harrington, Jinyu Kang, Fred Saad, Nuria Sala, Antoine Thiery-Vuillemin, Noel W. Clarke, Darren Hodgson, J. Carl Barrett
Publié 2021

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events base...

par Editorial Board
Publié 2021

Antiapoptotic and Anti-Inflammatory Effects of CPCGI in Rats with Traumatic Brain Injury

par Niu F, Qian K, Qi H, Zhao Y, Jiang Y, Sun M
Publié 2020

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

par Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, Alessia Anastasia, Massimo Russo, Giovanna Damia, Federica Guffanti, Francesca Guana, Paola Ostano, Lucia Minoli, Maureen M. Hattersley, Stephanie Arnold, Antonio Ramos-Montoya, Stuart C. Williamson, Alessandro Galbiati, Jelena Urosevic, Elisabetta Leo, Ugo Cavallaro, Carmen Ghilardi, Simon T. Barry, Maria Rosa Bani, Raffaella Giavazzi
Publié 2021

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

par Board Editorial
Publié 2021